Improving lung cancer immunotherapy using epigenetic approaches
Immunotherapy of cancer has advanced in leaps and bounds in recent years. In this guest blog, Anne Marie-Baird provides an update on some of the most important… Read more »
Queensland University of Technology, Australia
Dr Anne-Marie Baird researches mechanisms of cisplatin resistance in non-small cell lung cancer and targeted therapies for malignant pleural mesothelioma. Before her position at Queensland University of Technology, Baird was an International Association for the Study of Lung Cancer fellow in Trinity College Dublin/St. James’s Hospital.
Dr Anne-Marie Baird researches mechanisms of cisplatin resistance in non-small cell lung cancer and targeted therapies for malignant pleural mesothelioma. Before her position at Queensland University of Technology, Baird was an International Association for the Study of Lung Cancer fellow in Trinity College Dublin/St. James’s Hospital.
Latest posts by Dr Anne-Marie Baird (see all)
- Improving lung cancer immunotherapy using epigenetic approaches - 26th March 2015